Ongoing Litigation Regarding the Use of Cow's Milk Formulas and Necrotizing Enterocolitis: Issues of Product Liability and Proposed Requirement for Informed Consent.
T Allen Merritt, Kimberly Hillyer, Mitchell Goldstein, Joseph Hageman
{"title":"Ongoing Litigation Regarding the Use of Cow's Milk Formulas and Necrotizing Enterocolitis: Issues of Product Liability and Proposed Requirement for Informed Consent.","authors":"T Allen Merritt, Kimberly Hillyer, Mitchell Goldstein, Joseph Hageman","doi":"10.1089/bfm.2024.0321","DOIUrl":null,"url":null,"abstract":"<p><p>Recent litigation against the two major U.S. formula manufacturers regarding their products liability, in Gill v Abbott Laboratories and Watson v Mead Johnson, juries in two U.S. states have determined that these manufacturers' created products liability by their failure to warn parents and medical professionals that their formulas posed an increased risk for necrotizing enterocolitis (NEC). They asserted that their products are safe and effective. Juries in state courts in both cases awarded substantial monetary awards for punitive damage, economic and emotional harms to parents whose infant died after being fed \"premature special care formulas.\" The company's defense attorneys unsuccessfully asserted the doctrine of learned intermediaries, namely that it was neonatologists who ordered and/or administered these products to premature infants, thus causing NEC. The Food and Drug Administration (FDA) has regulatory authority over the formula manufacturing processes but does not grant \"approval\" status, as the FDA classifies these \"special care formulas\" as exempt because they are nutritional agents. While both cases are being appealed, the impact of these legal actions may discourage further \"special care formula\" development and may pose the future risk of physician malpractice allegations when an infant develops NEC after receiving a \"special care formula.\" In accordance with American Academy of Pediatrics recommendations, obtaining informed consent for formula use may mitigate some legal risks for neonatologists and other medical providers.</p>","PeriodicalId":9142,"journal":{"name":"Breastfeeding Medicine","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breastfeeding Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/bfm.2024.0321","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Recent litigation against the two major U.S. formula manufacturers regarding their products liability, in Gill v Abbott Laboratories and Watson v Mead Johnson, juries in two U.S. states have determined that these manufacturers' created products liability by their failure to warn parents and medical professionals that their formulas posed an increased risk for necrotizing enterocolitis (NEC). They asserted that their products are safe and effective. Juries in state courts in both cases awarded substantial monetary awards for punitive damage, economic and emotional harms to parents whose infant died after being fed "premature special care formulas." The company's defense attorneys unsuccessfully asserted the doctrine of learned intermediaries, namely that it was neonatologists who ordered and/or administered these products to premature infants, thus causing NEC. The Food and Drug Administration (FDA) has regulatory authority over the formula manufacturing processes but does not grant "approval" status, as the FDA classifies these "special care formulas" as exempt because they are nutritional agents. While both cases are being appealed, the impact of these legal actions may discourage further "special care formula" development and may pose the future risk of physician malpractice allegations when an infant develops NEC after receiving a "special care formula." In accordance with American Academy of Pediatrics recommendations, obtaining informed consent for formula use may mitigate some legal risks for neonatologists and other medical providers.
期刊介绍:
Breastfeeding Medicine provides unparalleled peer-reviewed research, protocols, and clinical applications to ensure optimal care for mother and infant. The Journal answers the growing demand for evidence-based research and explores the immediate and long-term outcomes of breastfeeding, including its epidemiologic, physiologic, and psychological benefits. It is the exclusive source of the Academy of Breastfeeding Medicine protocols.
Breastfeeding Medicine coverage includes:
Breastfeeding recommendations and protocols
Health consequences of artificial feeding
Physiology of lactation and biochemistry of breast milk
Optimal nutrition for the breastfeeding mother
Breastfeeding indications and contraindications
Managing breastfeeding discomfort, pain, and other complications
Breastfeeding the premature or sick infant
Breastfeeding in the chronically ill mother
Management of the breastfeeding mother on medication
Infectious disease transmission through breast milk and breastfeeding
The collection and storage of human milk and human milk banking
Measuring the impact of being a “baby-friendly” hospital
Cultural competence and cultural sensitivity
International public health issues including social and economic issues.